Vaxess Technologies Awarded NSF and NIH Grants

CAMBRIDGE, Massachusetts—Vaxess Technologies, Inc., an innovative life sciences company developing a novel silk protein-based vaccine technology, was awarded two separate Phase I Small Business Innovation Research Grants (SBIR) from the National Science Foundation (NSF) and the National Institute of Health (NIH).

Funding totaling $360,000 will go toward the development of novel heat-stable rotavirus and polio vaccines and advancement of innovative vaccine presentation formats.

Vaxess-Final-Press-Release-NSF-NIH-Grants
Fierce Vaccines